Latest news with #PEEK
Glasgow Times
25-07-2025
- Health
- Glasgow Times
NHSGGC encourage Glasgow families to keep children active
The health board is working with partners to highlight a range of free and low-cost activities across the region, designed to help children stay physically and mentally stimulated during the holidays. Anna Baxendale, head of health improvement at NHSGGC, said: "Physical activity is vital for children's mental wellbeing, cognitive development, and physical health. "Children who are active from a young age are more likely to maintain healthy habits into adulthood. "Active play, especially when it's fun, social, and self-directed, is the most common and effective form of exercise for children outside of school." Read more: Nurses in Glasgow could go on strike over pay dispute (Image: Supplied) (Image: Supplied) NHSGGC recognises that keeping children active throughout the summer can be challenging, especially for families facing financial pressures or juggling multiple children. The health board is sharing details of organised activities in communities, as well as ideas for active play that can be enjoyed at home. Anna said: "Our aim is to support families in finding free or low-cost ways to keep active in the summer months and beyond by sharing with them organised activities in their local area and creative, cost-free ideas that they can adopt for active play at home. "We are grateful to our partners and local authorities for creating and hosting these events, as well as developing at-home resources." NHSGGC is signposting families to resources that promote active play, including Play Scotland, Parent Club, and the HENRY programme. The HENRY programme, delivered in partnership with Early Years Scotland (EYS) and PEEK (Possibilities for Each and Every Kid), is designed to bring practical support directly into communities. This summer, EYS is running free Step Into Summer sessions across the region, featuring sensory play, arts and crafts, and outdoor activities. Read more: Project to explore viability of self-driving bus service in Glasgow PEEK will also host a Play Day on July 30 at Crownpoint Sports Complex, offering go-karting, crafts, outdoor games, and a silent disco. NHSGGC also works with local authority leisure providers offering holiday programmes, free play sessions, and discounted court hire. Families in Glasgow can take advantage of Glasgow Life's Summer of Fun, which includes free family swimming, sports camps, and games sessions at local sports centres. Further details about NHSGGC programmes, including Thrive Under Five and HENRY, are available on the Child and Young Persons' Healthy Weight section of the NHSGGC website.
Yahoo
16-07-2025
- Business
- Yahoo
Increasing Demand for Bio-based Grades and Growing Penetration of Reinforced 3D Printing High-Performance Plastics
The 3D printing high-performance plastics market is set to grow significantly from USD 0.18 billion in 2025 to USD 0.45 billion by 2030, with a CAGR of 20.4%. This growth is fueled by the rising demand for polyamide-based plastics, crucial in medical, automotive, and aerospace applications. Polyamides are favored for their mechanical and thermal properties, enhancing technologies like Selective Laser Sintering for efficient additive manufacturing. North America is projected to lead the growth, driven by industrial adoption and innovative applications. Key players, including Evonik and Arkema, are pivotal in this advancing market. 3D Printing High-Performance Plastic Market Dublin, July 16, 2025 (GLOBE NEWSWIRE) -- The "3D Printing High-Performance Plastic Market by Type, Form, Technology, Application, End-use Industry, and Region - Global Forecast to 2030" has been added to offering. The 3D printing high-performance plastics market is poised for significant growth, with projections jumping from USD 0.18 billion in 2025 to USD 0.45 billion by 2030, exhibiting a CAGR of 20.4%. The driving force behind this surge is the escalating demand for polyamide-based high-performance plastics, valued for their mechanical, thermal, and processing prowess. Market leaders and new entrants will benefit from this report by understanding revenue approximations and market subsegments. Stakeholders will gain a clearer understanding of the competitive landscape and strategic insights to effectively position their businesses. The analysis provides data on market drivers, restraints, challenges, and opportunities. Polyamides are highly compatible with powder bed fusion (PBF) technologies like Selective Laser Sintering (SLS), recognized for their capacity to economically produce complex, lightweight, and sturdy components with minimal material waste. In the realms of medicine and healthcare, 3D-printed polyamide applications extend to surgical tools, bespoke prosthetics, orthopedic implants, and anatomical models, thanks to their biocompatibility and ability to withstand sterilization, allowing customization for patient-specific needs. The automotive and aerospace sectors are increasingly reliant on polyamide-based materials to achieve rigorous performance and efficiency targets. These materials, with high strength-to-weight ratios, enable the crafting of components that support fuel efficiency and emission reduction while retaining structural integrity under intense conditions. This propels polyamide's prominence within the high-performance 3D printing arena. The aerospace & defense industry is set to be one of the quickest-growing sectors during the forecast period. The sector is invigorated by the demand for materials that deliver durability, thermal resistance, and efficiency. High-performance plastics like PEEK, PEKK, and PEI offer superb strength-to-weight ratios, facilitating the replacement of traditional metal parts with lighter alternatives, without sacrificing performance. Additive manufacturing enhances these materials' benefits by enabling intricate designs, minimizing assembly complexity, and optimizing part functionality - immensely beneficial in aerospace and defense domains. North America is anticipated to register the highest growth rate in this market during the forecast period. Propelled by robust industrial adoption and continuous innovation, North America stands at the forefront of 3D printing advancements. The region's key industries, including aerospace, automotive, and healthcare, increasingly exploit 3D printing for both prototyping and large-scale production involving high-performance plastics such as PEEK, PEKK, and PEI. Manufacturers in North America embrace additive manufacturing to bolster design flexibility, shorten lead times, reduce material waste, and promote on-demand, localized production. This not only aligns with agile manufacturing strategies but also bolsters supply chain resilience, placing the region at the cutting edge of global technological progress. Key Attributes: Report Attribute Details No. of Pages 335 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $0.18 Billion Forecasted Market Value (USD) by 2030 $0.45 Billion Compound Annual Growth Rate 20.4% Regions Covered Global Market Dynamics Drivers Increasing Applications in Medical & Healthcare, Aerospace & Defense, and Automotive Industries Development of Application-Specific Grades for 3D Printing High-Performance Plastics Government Initiatives to Support Adoption in Different Industries Rising Investments and Favorable Policies for Sustainable Solutions Restraints Environmental Concerns Regarding Disposal of 3D-Printed Plastic Products Skepticism About Acceptance of New Technologies in Emerging Economies Opportunities Increasing Demand for Bio-based Grades of 3D Printing High-Performance Plastics Growing Penetration of Reinforced 3D Printing High-Performance Plastics in Manufacturing Functional Parts Challenges High Manufacturing Cost of Commercial Grades of 3D Printing High-Performance Plastics Prolonged Lead Time Case Studies to Develop Materials for Aerospace and Automotive Industries to Produce Good-Quality Complex Parts at Rapid Pace Lockheed Martin and High-Performance Thermoplastics Evonik Introduced World's First Pa12 Powder for 3D Printing Based on Bio-Circular Raw Material Trends and Disruptions Trends and Disruptions Impacting Customer Business Company Profiles Evonik Industries Arkema Lehmann&Voss&Co. Nano Dimensions (Markforged) Oxford Performance Materials Eos GmbH Solvay Sabic Forward Am Technologies GmbH Impossible Objects Apium Additive Technologies GmbH Ensinger Victrex PLC Mitsubishi Chemical Corporation Toray Industries, Inc. Proto Labs 3Dxtech Zortrax Treed Filaments Formlabs Eplus3D Junhua Peek Sculpteo Peekchina For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment 3D Printing High-Performance Plastic Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Indianapolis Star
01-07-2025
- Business
- Indianapolis Star
Hogge Precision Reinforces Leadership in Medical CNC Machining with Advanced Capabilities and Industry Expertise
Hogge Precision, a leading provider of high-precision manufacturing solutions, today highlighted its advanced medical CNC machining capabilities, underscoring its commitment to delivering exceptional components tailored for critical medical applications. As an ISO 9001:2015 registered manufacturer, Hogge Precision solidifies its position as a trusted partner to healthcare innovators, producing intricate, reliable parts that meet rigorous quality standards essential for medical devices and components. The company's adherence to strict regulatory requirements ensures that every piece manufactured supports the advancement of healthcare technology with uncompromising accuracy and consistency. Medical device manufacturers face stringent demands when sourcing components that require ultra-tight tolerances, biocompatible materials, and flawless performance under critical conditions. Hogge Precision addresses these challenges by leveraging the latest CNC machining technologies combined with decades of experience to transform complex designs into precision-engineered parts. The company's commitment to quality is deeply rooted in its comprehensive understanding of the medical industry's exacting standards, reaffirmed through its ISO 9001:2015 certification, which governs process validation and traceability. At the core of Hogge Precision's capabilities lies a robust portfolio of manufacturing technologies. Utilizing advanced Swiss CNC machining, the company excels in producing small, complex components that demand exceptional precision, such as those used in handheld surgical instruments. Multi-axis CNC turning and milling further expand their capacity to produce a diverse range of geometries, from simple components to highly intricate parts designed for innovative medical tools and diagnostic equipment. Material expertise is another fundamental aspect of Hogge Precision's offering. The company is proficient in machining a broad spectrum of medical-grade metals and polymers crucial for medical applications. These include stainless steel and titanium, prized for their biocompatibility and strength, as well as advanced plastics like PEEK and Delrin, known for their durability and resistance to bodily fluids. This versatility in materials enables Hogge Precision to meet various medical device requirements, whether for surgical tools or drug delivery mechanisms where material purity and precision are paramount. Hogge Precision is capable of supporting projects throughout the entire production lifecycle, from initial prototyping and design validation to full-scale manufacturing runs. This seamless transition from prototype to production helps medical device developers accelerate time-to-market while ensuring parts meet all functional and regulatory specifications. The company's collaborative approach with clients includes detailed design-for-manufacturability support, helping optimize product designs to ensure efficiency, cost-effectiveness, and manufacturability without compromising quality or performance. The scope of medical components produced by Hogge Precision spans a wide array of critical applications. The company supplies specialized parts for surgical instruments used in orthopedic procedures, such as instruments for installing bone screws and plates, where precision directly impacts surgical outcomes. Furthermore, it manufactures components integral to drug delivery systems, including insulin pens, which require precision dosing mechanisms and high reliability. In diagnostic and monitoring equipment, Hogge Precision produces electrical and mechanical parts that contribute to accurate patient diagnostics and safety. Danny Hogge Jr, President of Hogge Precision, commented on the company's capabilities: 'Our focus has always been on delivering precision and reliability in every component we manufacture for the medical industry. Hogge Precisions' medical machining capabilities combine advanced technology, rigorous quality systems, and decades of expertise to support devices that improve patient lives. We understand the critical nature of these applications and are committed to partnering closely with our clients to help them meet demanding standards and innovate in healthcare.' Continuous investment in state-of-the-art CNC machinery and quality control equipment has allowed Hogge Precision to maintain a competitive edge in the evolving medical manufacturing landscape. The company employs cutting-edge inspection tools and process monitoring to guarantee component consistency and traceability, vital to maintaining compliance with regulatory agencies. These stringent controls ensure customers receive parts of the highest caliber that stand up to the scrutiny required in medical device manufacturing. The company's extensive experience, combined with its collaborative approach, enables it to cater to both startups developing innovative medical solutions and established global manufacturers requiring high-volume production. Hogge Precision's reliability and expertise have made it a preferred partner for OEMs and medical suppliers that demand precision, efficiency, and quality.
Yahoo
12-06-2025
- Business
- Yahoo
SINTX Technologies Announces Strategic Vision Focused on Expansion Across Key Sectors
New leadership and recapitalization to accelerate commercialization of proprietary silicon nitride technologies in medical and high-growth markets SALT LAKE CITY, Utah, June 12, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) ('SINTX' or the 'Company'), the only FDA-registered producer of implantable silicon nitride and a global leader in advanced ceramics, today announced a renewed corporate vision and strategic plan to accelerate commercialization and unlock the full value of its intellectual property portfolio. This follows the company's successful recapitalization in February 2025 and the restructure of its leadership team and Board of Directors. A Legacy of Innovation in Silicon Nitride In 2008 SINTX Technologies made history with the first FDA-cleared implant material that is neither metal nor plastic—but medical-grade silicon nitride. The initial clearance covered a family of interbody devices and marked a pivotal moment in spinal surgery. These implants offered a unique trifecta of benefits: antimicrobial activity, osteogenic potential, and radiographic translucency. With over 50,000 spinal implants successfully placed worldwide, SINTX has demonstrated the clinical viability and long-term advantages of this revolutionary biomaterial. Today, SINTX remains the industry leader in silicon nitride technology, with 18 issued U.S. patents and 84 pending applications. Known for its strength, biocompatibility, and infection-resistant properties, the company's proprietary ceramic platform has applications across multiple markets—including the $62 billion global orthopedic implant sector, as well as emerging fields like agribiotech and performance textiles. Renewed Vision and Mission SINTX is now taking this one step further by developing next-generation hybrid biomaterials that combine the biological performance of silicon nitride and merging the flexibility, and manufacturability of polymers like PEEK and PEKK. These new composites are being optimized for applications in spine, oral/maxillofacial (OMF), cranio-maxillofacial (CMF), and oncologic reconstruction. 'Our mission is clear: to drive sustainable growth and value creation by collaborating with market leaders who recognize the transformative potential of silicon nitride,' said Mr. Eric Olson, CEO of SINTX Technologies. 'With a strengthened balance sheet and a robust intellectual property portfolio, we are uniquely positioned to accelerate commercialization and deliver superior outcomes for patients, customers, and shareholders alike.' Strategic Initiatives and Market Expansion SINTX is actively pursuing strategic partnerships and licensing opportunities to expand the reach of its technology. The company's near-term focus includes: Joint Ventures: Collaborating with established manufacturers in orthopedics, wound care, agribiotech, and other potential sectors to integrate silicon nitride into next-generation products. IP Monetization: Unlocking value from its extensive patent portfolio through licensing agreements and technology transfer initiatives. Operational Excellence: Enhancing AI supported 3D manufacturing capabilities at its FDA cleared and ISO certified headquarters to support anticipated growth and ensure the highest quality standards. Commitment to Stakeholders As SINTX enters this new era, the Company reaffirms its commitment to transparency, disciplined execution, and long-term value creation for all stakeholders. 'We are grateful for the continued support of our shareholders and partners,' said Mr. Olson. 'Together, we will realize the full potential of silicon nitride and secure SINTX's position as a leader in advanced ceramics. For more information, please visit About SINTX Technologies, Inc. Located in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter new markets. For more information on SINTX Technologies or its materials platform, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ('PSLRA') that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy,' "future," "likely," "may," "should," "will" and similar references to future periods. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. Forward looking statements include our efforts to develop next-generation hybrid biomaterials, our expectation that will drive sustainable growth and value creation, and that we will expand the reach of our technology pursuing strategic partnerships and licensing opportunities. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulty in developing and commercializing medical device technologies. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 19, 2025, and in SINTX's other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law. Business and Media Inquiries for SINTX:SINTX Technologies, Inc. 801.839.3502IR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-06-2025
- Business
- Yahoo
60% return! Is this FTSE 250 growth stock about to skyrocket?
The FTSE 250 index has been a bit flat so far in 2025. However, that doesn't mean its constituent businesses haven't been making good progress. And Deutsche Bank has spotted one company it believes is primed to surge. So much so that earlier in the year its team of analysts issued a Buy recommendation with a share price target that suggests a 60% gain is potentially on the horizon for fast-acting investors. The FTSE 250 stock in question is Victrex (LSE:VCT). And over the last five years, the stock's hardly been a money maker for shareholders, given its market-cap has been more than slashed in half. But that doesn't mean it still can't be a lucrative investment today. After all, a successful turnaround by management could deliver substantial recovery gains. That certainly seems to be what Deutsche's betting on. To be fair, there are early signs a recovery's underway. Industrial demand for the firm's unique PEEK polymers is back on the rise, with inventory-destocking headwinds steadily coming to an end. Subsequently, production volumes have been restored to 2022 levels. And at the same time, operating optimisations and efficiencies have paved the way for superior free cash flow generation, while revenue growth has returned, albeit by a small amount. Needless to say, that's a welcome change of pace compared to the lacklustre results the company has been delivering in recent years. This likely also explains why other analysts have begun reassessing their recommendations to be more bullish. Getting in early before a stock recovery kicks off can be very lucrative, paving the way for substantial double-digit gains. However, that also comes with risk if the underlying business can't keep up with expectations. In the case of Victrex, the company isn't out of the woods quite yet. Its highly-anticipated China production facility was recently completed, expanding the firm's reach into Asian markets. But so far, manufacturing challenges have prevented it from operating at full capacity. Consequently, management's production forecast for its 2025 fiscal year (ending in September) was slashed from up to 200 polymer tonnes to just 50 tonnes. Furthermore, with lower-margin valued added reseller customers driving the bulk of new demand, profits have yet to move back in the right direction. And with concerns that further challenges may lie ahead, the analyst team at Jefferies has changed its recommendation from Hold to Underperform. In other words, not every institutional analyst is convinced Victrex is on the verge of a rebound. Conflicting opinions among analysts is nothing new in the stock market. However, in the case of Victrex, I think some healthy scepticism is warranted. The firm's track record of hitting targets has been a bit patchy of late. And if that pattern continues moving forward, the FTSE 250 stock's recovery may not be as close as some analysts believe. With that in mind, I'm keeping this business on my watchlist for now. The post 60% return! Is this FTSE 250 growth stock about to skyrocket? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has recommended Victrex Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
